

DR. REDDY'S LABORATORIES LTD.

8-2-337, Road No. 3, Banjara Hills,
Hyderabad - 500034. Telangana, India.

CONTACT

MEDIA RELATIONS

USHA IYER
USHAIYER@DRREDDYS.COM

Akhil Ravi appointed CEO of Aurigene Pharmaceutical Services Ltd.

Hyderabad, India, February 1, 2022

Hyderabad, India, February 1, 2022 - Dr. Reddy's Laboratories Ltd. along with its subsidiaries together referred to as "Dr. Reddy's") today announced that it named Akhil Ravi as CEO for its wholly-owned subsidiary Aurigene Pharmaceutical Services Ltd. (APSL) effective February 1, 2022.

Since joining Dr. Reddy's in 2018 from McKinsey & Company, Akhil Ravi has served as Head of Strategy for Services and Active Pharmaceutical Ingredients (APIs), and headed the Sales of APIs in Europe. In addition, he has also had a brief stint as Plant Head. Akhil holds a BTech degree in Chemical Engineering from IIT Bombay and an MBA from the Indian School of Business (ISB).

"Akhil is very well prepared for this role. He was instrumental in growing our API business through product development and an improved service experience for our B2B customers through digital platforms. His strong background in customer service, sales, strategy, and management make him an ideal leader for Aurigene, and we look forward to his accomplishments in this new role." said Deepak Sapra, CEO of API and Services at Dr. Reddy's, and Member of the Board at Aurigene.

Akhil Ravi said: "Aurigene Pharmaceutical Services is a dynamic partner for global pharma companies. With its integrated services from clinical research up to commercial manufacturing for small and large molecules, it is able to significantly speed up the journey of an NCE/NBE (New Chemical and Biological Entities) to the patient. I am very thrilled to join Aurigene and work with the team to serve innovative global pharma and biotech companies."

About Aurigene Pharmaceutical Services Ltd. (APSL):

Aurigene Pharmaceutical Services Limited (APSL) is an integrated partner for global pharma companies. It covers the entire value chain for new therapeutics, from drug discovery, clinical research, and development to manufacturing APIs and formulation at commercial scales. It has development laboratories from discovery to clinical phase III for New Chemical and Biological Entities (NCEs/NBEs) and cGMP manufacturing facilities in the UK, Mexico, USA, and India.

About Dr. Reddy's: Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its businesses, Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers', products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread

illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements" sections of our Annual Report on Form 20-F for the year ended March 31, 2021. The company assumes no obligation to update any information contained herein.

|